Prime Medicine, Inc. (PRME)
NASDAQ: PRME · IEX Real-Time Price · USD
5.31
-0.27 (-4.76%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Prime Medicine Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Prime Medicine stock have an average target of 15.7, with a low estimate of 10 and a high estimate of 20. The average target predicts an increase of 195.95% from the current stock price of 5.31.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 20, 2024.
Analyst Ratings
The average analyst rating for Prime Medicine stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 7 | 7 | 7 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 9 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +88.50% | May 20, 2024 |
| Citigroup | Citigroup | Hold → Strong Buy Upgrades $10 | Hold → Strong Buy | Upgrades | $10 | +88.50% | May 16, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $16 → $15 | Buy | Maintains | $16 → $15 | +182.75% | May 13, 2024 |
| Jefferies | Jefferies | Strong Buy Initiates $23 → $15 | Strong Buy | Initiates | $23 → $15 | +182.75% | May 7, 2024 |
| Wedbush | Wedbush | Buy Reiterates $12 | Buy | Reiterates | $12 | +126.20% | Apr 23, 2024 |
Financial Forecast
Revenue This Year
4.91M
Revenue Next Year
4.47M
from 4.91M
Decreased by -8.90%
EPS This Year
-1.72
from -2.18
EPS Next Year
-1.57
from -1.72
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 42.0M | 37.6M | 8.1M | 187.9M | 262.9M |
| Avg | 4.9M | 4.5M | 1.3M | 27.2M | 41.2M |
| Low | 579,180 | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 665.9% | 80.8% | 14,856.2% | 864.9% |
| Avg | - | -8.9% | -71.9% | 2,069.5% | 51.1% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.53 | -1.19 | -1.47 | -0.62 | -0.33 |
| Avg | -1.72 | -1.57 | -1.63 | -1.32 | -1.17 |
| Low | -1.78 | -1.76 | -1.89 | -1.50 | -1.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.